Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis.

@article{Arai2014PredictorsOT,
  title={Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis.},
  author={Toru Arai and Yoshikazu Inoue and Yumiko Sasaki and Kazunobu Tachibana and Keiko Nakao and Chikatoshi Sugimoto and Tomohisa Okuma and Masanori Akira and Masanori Kitaichi and Seiji Hayashi},
  journal={Respiratory investigation},
  year={2014},
  volume={52 2},
  pages={136-43}
}
BACKGROUND Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a poor prognosis. Recently, pirfenidone was reported to slow the rate of decline in vital capacity and improve progression-free survival in IPF. The purpose of this study was to clarify the factors that predicted a good response to pirfenidone, as well as its adverse effects. METHODS Forty-one IPF cases, treated with pirfenidone from January 2009 to January 2011, were enrolled in this investigation… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences.

European respiratory review : an official journal of the European Respiratory Society • 2015

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Pirfenidone in idiopathic pulmonary fibrosis.

The European respiratory journal • 2010
View 19 Excerpts
Highly Influenced

Ameliorative effects of mosapride or Rikkunshi-to on the suppression of gastrointestinal motility by pirfenidone

T Itoh, K Koyabu, A Morimoto
Jpn Pharmacol Ther 2012;40:405–11 • 2012
View 2 Excerpts

Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis.

European respiratory review : an official journal of the European Respiratory Society • 2012
View 2 Excerpts

Similar Papers

Loading similar papers…